Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalty payments
Biotech
Royalty bestows Zenas with $300M for autoimmune approval push
Royalty is paying Zenas $75 million upfront, with similar payments coming if obexelimab succeeds in phase 3 and secures FDA approval.
Darren Incorvaia
Sep 2, 2025 11:07am
RegenXBio sells $250M of paydays for Zolgensma, other therapies
May 20, 2025 7:15am
Investors say 'no bueno' to Cytokinetics' complex Royalty deal
May 23, 2024 10:36am
BridgeBio taps investors for $1.25B to fund showdown with Pfizer
Jan 18, 2024 8:04am
ImmunityBio inks $210M royalty deal to get cancer drug to market
Jan 2, 2024 7:41am
Royalty swoops in with $100M upfront for slice of Karuna's KarXT
Mar 23, 2023 9:45am
